Janus Global Life Sciences J
151 Detroit Street Denver CO 80206
Map
Phone: 800-525-0020
| Category: | Health | | Fund Family: | Janus | | Net Assets: | 672.88M | | Year-to-Date Return: | 19.33% | | Yield: | 0.31% | | Morningstar Rating: |  | | Fund Inception Date: | 31-Dec-98 |
|
Andrew Acker
Lead Manager since
01-May-07 | | | Acker joined Janus Capital in 1999 as a securities analyst. He is a portfolio manager at the firm. Acker holds the Chartered Financial Analyst designation. |
| Min Initial Investment: | $2,500 | | Min Initial Investment, IRA: | $1,000 | | Min Initial Investment, AIP: | $500 | | Min Subsequent Investment: | $100 | | Min Subsequent Investment, IRA: | $100 | | Min Subsequent Investment, AIP: | $100 |
|
| |
| The investment seeks long-term growth of capital. The fund normally invests at least 80% of net assets in securities of companies that the portfolio manager believes have a life science orientation. It normally invests in issuers from several different countries, which may include the United States. The fund may, under unusual circumstances, invest in a single country. It normally invests at least 25% of total assets in the "life sciences" sector. The fund may have significant exposure to emerging markets. |
| Last Dividend
(24-Jun-09):
| 0.04 | | Last Cap Gain
| YFT_NOT_APPLICABLE_ABBREVIATION | | Annual Holdings Turnover
| YFT_NOT_APPLICABLE_ABBREVIATION | | Average for Category:
| 109.30% |
|
| Expense | JAGLX | Category
Avg | | Total Expense Ratio: | 0.98%
| 1.67% | | Max 12b1 Fee: | %
| N/A | | Max Front End Sales Load: | %
| 5.35% | | Max Deferred Sales Load: | %
| 2.88% | | 3 Yr Expense Projection*: |
$ 312 | $716 | | 5 Yr Expense Projection*: |
$ 542 | $1,069 | | 10 Yr Expense Projection*: |
$ 1,201 | $2,090 |
|
|
0.20% Nasdaq 
0.14%
Profile
